You are here

Suzanne Jacobs


Rusu V, Hoch E, et al. Type 2 diabetes variants disrupt function of SLC16A11 through two distinct mechanisms. Cell. 2017; 170(1): 199-212.

Mercader JM, et al. A loss-of-function splice acceptor variant in IGF2 is protective for type 2 diabetes. Diabetes. 2017; 66(11): 2903-2914.

SIGMA Type 2 Diabetes Consortium, et al. Sequence variants in SLC16A11 are a common risk factor for type 2 diabetes in Mexico. Nature. 2014; 506(7486): 97-101.

Flannick J, et al. Loss-of-function mutations in SLC30A8 protect against type 2 diabetes. Nature Genetics. 2014; 45(4): 357-363.

SIGMA Type 2 Diabetes Consortium, et al. Association of a low-frequency variant in HNF1A with type 2 diabetes in a Latino population. JAMA. 2014; 311(22): 2305-14.

Suzanne Jacobs, Ph.D.

Suzanne Jacobs is the associate scientific director for the Diabetes Research Group, and a member of the Medical and Population Genetics and Metabolism Programs at the Broad Institute of MIT and Harvard, where she is also an institute scientist. In these roles, Jacobs works closely with institute member Jose Florez to lead a multidisciplinary research program that aims to determine genetic contributors to type 2 diabetes, and to translate this knowledge into improved patient care through the development of novel therapeutics and a clinical understanding of how genetic variation influences human physiology and therapeutic response.

Jacobs’s research group focuses on functionally validating genetic influences on disease as potential therapeutic targets. This is accomplished through the development and use of diverse biochemical, molecular, and cellular methods and animal models to determine the function of disease-associated genes, the impact of genetic variation on gene and protein function, and the consequences of these effects on cellular metabolism and physiology. The goals are to identify causal genes and variants as well as the molecular, cellular, and physiological mechanisms that lead to disease, as these could represent important therapeutic targets for those with — or at risk for developing — type 2 diabetes.

Prior to joining the Broad Institute in 2010, Jacobs completed her postdoctoral work with Laura Attardi at the Stanford University School of Medicine’s Department of Radiation Oncology. Jacobs received her bachelor’s degree in biological sciences from Northwestern University and earned a Ph.D. in biomedical sciences from the University of California, San Diego.

Contact Suzanne Jacobs via email at

March 2021